Common challenges facing drug development and reimbursement for rare diseases

Common challenges facing drug development and reimbursement for rare diseases

Common challenges facing drug development and reimbursement for rare diseases

Approximately 90% of rare diseases still have no effective treatments, despite regulators implementing expedited approval pathways for these indications.